loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Venus Remedies Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Venus Remedies Ltd. 27 Oct 2026 12:31 PM

Q2FY27 Quarterly Result Announced for Venus Remedies Ltd.

Pharmaceuticals company Venus Remedies announced Q2FY27 results

Consolidated Financial Highlights:

  • Revenue from operations was Rs 218.76 crore in Q2FY27, up by 22.31% QoQ compared to Rs 178.86 crore in Q1FY27 and up by 13.43% YoY from Rs 192.75 crore in Q2FY25. For H1FY27, consolidated revenue from operations reached Rs 397.62 crore, showing a YoY growth of 20.52% from Rs 329.93 crore in H1FY25.
  • Total income stood at Rs 219.27 crore in Q2FY27, showing a sequential growth of 20.82% QoQ against Rs 181.48 crore in Q1FY27 and an expansion of 12.76% YoY against Rs 194.46 crore in Q2FY25. For H1FY27, total income recorded was Rs 400.75 crore, up by 19.61% YoY over Rs 335.05 crore in H1FY25.
  • Profit before tax (PBT) stood at Rs 33.47 crore in Q2FY27, increasing by 11.42% QoQ compared to Rs 30.04 crore in Q1FY27 and growing by 26.35% YoY from Rs 26.49 crore in Q2FY25. For H1FY27, PBT reached Rs 63.51 crore, showing a YoY increase of 62.47% from Rs 39.09 crore in H1FY25.
  • Profit after tax (PAT) was Rs 25.65 crore in Q2FY27, growing by 11.67% sequentially against Rs 22.97 crore in Q1FY27 and growing by 27.42% YoY from Rs 20.13 crore in Q2FY25. For H1FY27, consolidated PAT stood at Rs 48.62 crore, translating to a YoY increase of 63.54% compared to Rs 29.73 crore in H1FY25.
  • Earnings per share (EPS) basic and diluted stood at Rs 19.19 in Q2FY27, up by 11.70% sequentially against Rs 17.18 in Q1FY27 and higher by 27.42% YoY compared to Rs 15.06 in Q2FY25. For H1FY27, basic and diluted EPS reached Rs 36.37, expanding by 63.53% YoY against Rs 22.24 in H1FY25.

Standalone Financial Highlights:

  • Revenue from operations reached Rs 218.76 crore in Q2FY27, scaling up by 22.35% QoQ from Rs 178.80 crore in Q1FY27 and increasing by 13.55% YoY compared to Rs 192.65 crore in Q2FY25. For H1FY27, standalone revenue from operations stood at Rs 397.55 crore, increasing by 20.55% YoY over Rs 329.78 crore in H1FY25.
  • Total income stood at Rs 219.16 crore in Q2FY27, up by 20.85% sequentially QoQ against Rs 181.35 crore in Q1FY27 and increasing by 12.78% YoY from Rs 194.33 crore in Q2FY25. For H1FY27, standalone total income reached Rs 400.50 crore, expanding by 19.85% YoY compared to Rs 334.18 crore in H1FY25.
  • Profit before tax (PBT) was Rs 36.77 crore in Q2FY27, up by 12.76% QoQ from Rs 32.61 crore in Q1FY27 and growing by 43.63% YoY from Rs 25.60 crore in Q2FY25. For H1FY27, PBT stood at Rs 69.35 crore, recording a YoY expansion of 72.04% over Rs 40.31 crore in H1FY25.
  • Profit after tax (PAT) stood at Rs 28.96 crore in Q2FY27, demonstrating a QoQ increase of 13.43% against Rs 25.53 crore in Q1FY27 and a YoY expansion of 50.52% from Rs 19.24 crore in Q2FY25. For H1FY27, standalone PAT reached Rs 54.46 crore, recording a 75.96% YoY growth against Rs 30.95 crore in H1FY25.
  • Earnings per share (EPS) basic and diluted was Rs 21.66 in Q2FY27, displaying a sequential expansion of 13.40% QoQ over Rs 19.10 in Q1FY27 and increasing by 50.42% YoY against Rs 14.40 in Q2FY25. H1FY27 basic and diluted EPS reached Rs 40.74, up 75.98% YoY compared to Rs 23.15 in H1FY25.

Result PDF

Pharmaceuticals company Venus Remedies announced Q4FY26 & FY26 results

Standalone Financial Highlights:

  • Revenue from operations:
    • For Q4FY26, the company reported revenue of Rs 259.01 crore, reflecting a QoQ increase of 43.94% (vs Q3FY26: Rs 179.95 crore) and a YoY increase of 31.65% (vs Q4FY25: Rs 196.74 crore).
    • For FY26, the revenue from operations stood at Rs 768.73 crore, an annual growth of 19.28% compared to FY25 (Rs 644.47 crore).
  • Total Income:
    • Total income for Q4FY26 was Rs 263.64 crore, a QoQ growth of 44.57% (vs Q3FY26: Rs 182.36 crore) and a YoY growth of 31.29% (vs Q4FY25: Rs 200.81 crore).
    • For FY26, the total income was Rs 780.19 crore, up 18.17% from FY25 (Rs 660.24 crore).
  • Net Profit for the period:
    • The profit for Q4FY26 was Rs 43.45 crore, reflecting a QoQ increase of 74.36% (vs Q3FY26: Rs 24.92 crore) and a YoY increase of 193.78% (vs Q4FY25: Rs 14.79 crore).
    • For FY26, the net profit stood at Rs 99.31 crore, showing a growth of 89.00% compared to FY25 (Rs 52.55 crore).
  • Earnings Per Share (EPS): The basic EPS for Q4FY26 was Rs 32.51, and For FY26, it was Rs 74.29.

Consolidated Financial Highlights:

  • Revenue from operations:
    • For Q4FY26, the consolidated revenue was Rs 259.40 crore, an increase of 43.90% QoQ (vs Q3FY26: Rs 180.26 crore) and 31.24% YoY (vs Q4FY25: Rs 197.66 crore).
    • For FY26, the consolidated revenue was Rs 769.60 crore, a growth of 17.88% compared to FY25 (Rs 652.89 crore).
  • Total Income:
    • Total consolidated income for Q4FY26 was Rs 264.35 crore, reflecting a QoQ increase of 44.63% (vs Q3FY26: Rs 182.78 crore) and a YoY increase of 31.04% (vs Q4FY25: Rs 201.73 crore).
    • For FY26, the total income was Rs 782.18 crore, compared to Rs 668.84 crore in FY25, an increase of 16.95%.
  • Net Profit (Attributable to Owners):
    • The consolidated net profit attributable to the owners of the company for Q4FY26 was Rs 40.68 crore, compared to Rs 32.39 crore in Q3FY26 (a QoQ increase of 25.59%) and Rs 11.67 crore in Q4FY25 (a YoY increase of 248.59%).
    • For FY26, the net profit attributable to owners was Rs 135.37 crore, an increase of 69.09% compared to FY25 (Rs 80.06 crore).
  • Earnings Per Share (EPS): The basic EPS for Q4FY26 was Rs 35.53, and For FY26, it was Rs 76.89.

Business Highlights:

  • Segment Performance: The company operates in a single reportable segment, namely "Pharmaceuticals".
  • Dividend: The Board has recommended a final dividend of Rs 10 per equity share (100% of face value of Rs 10 each) for FY26, subject to shareholder approval at the 37th Annual General Meeting.
  • Subsidiaries: The company has a wholly-owned subsidiary, Venus Pharma GmbH in Germany, and a step-down subsidiary, Venus Pharma Kft in Hungary.
  • Key Appointments: Mr. Saransh Chaudhary and Dr. Gurminder Singh Bedi were appointed as Additional Directors. Ms. Meenakshi Bishnoi was re-appointed as Chief Compliance Officer, and Mr. Kartik Chawda was appointed as Chief Information Officer & Head of IT, effective June 01, 2026.

Result PDF

Pharmaceuticals company Venus Remedies announced Q3FY26 results

  • Revenue: Rs 180.26 crore against Rs 176.52 crore during Q3FY25, change 2%.
  • PBT: Rs 33.47 crore against Rs 14.97 crore during Q3FY25, change 124%.
  • PAT: Rs 25.58 crore against Rs 19.6 crore during Q3FY25, change 31%.
  • EPS: 19.14 for Q3FY26.

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app